Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – What’s Next?

Fresenius SE & Co. (OTCMKTS:FSNUYGet Free Report)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $15.33, but opened at $15.94. Fresenius SE & Co. shares last traded at $15.38, with a volume of 2,671 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on FSNUY shares. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, December 15th. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Monday, October 27th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Read Our Latest Stock Analysis on Fresenius SE & Co.

Fresenius SE & Co. Stock Performance

The company has a fifty day moving average of $14.49 and a two-hundred day moving average of $14.34. The firm has a market capitalization of $34.70 billion, a price-to-earnings ratio of 28.00 and a beta of 0.75. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.99 and a current ratio of 1.26.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

Featured Articles

Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.